Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott and Reata to ally on kidney disease treatment development

Abbott and Reata to ally on kidney disease treatment development

24th September 2010

Abbott is entering into a collaboration with Reata Pharmaceuticals over the development of a new treatment for the chronic kidney disease (CKD) drug bardoxolone methyl.

The deal will see Abbott gain exclusive development and commercialisation rights to a promising first-in-class oral antioxidant inflammation modulator, which helps to increase the estimated glomerular filtration rate of the kidneys.

It has been shown in phase II clinical trials to be effective in improving kidney function among patients with CKD and type 2 diabetes.

The agreement is applicable in all territories other than the US and certain Asian markets and also grants Abbott development rights to a number of other Reata compounds for CKD, cardiovascular and metabolic diseases.

Dr John Leonard, senior vice-president for pharmaceuticals research and development at Abbott, said: "Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis."

Earlier this week, Abbott was recognised by business publication The Deal as one of the industry's most admired dealmakers, thanks to its success in expanding the business via new acquisitions and mergers.ADNFCR-8000103-ID-800081023-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.